HomeINTEGRA BiosciencesINTEGRA Biosciences Takes Decisive Step in Sustainability

INTEGRA Biosciences Takes Decisive Step in Sustainability

INTEGRA Biosciences has made significant progress towards its goal of minimizing its ecological footprint with the installation of new photovoltaic systems at the company’s US facilities in Hudson, NH.

These systems will provide 77 percent of the total energy requirement for both the company’s US headquarters and production center, saving as much CO2 as 2900 cars or 2300 single-family homes produce in the USA each year.

INTEGRA first introduced photovoltaic systems at its global headquarters in Zizers, Switzerland, in 2019. Combined with extensive use of Swiss hydropower, this ensures that the Zizers site – including heating and cooling – is run entirely with renewable energy.

Expanding this approach to its US facilities, INTEGRA has now completed the installation of almost 1500 panels with double-sided solar cells on the roofs of its two buildings in Hudson. Capable of producing 817,000 kWh per year, they are expected to produce more than 19 million kWh over their service life.

This latest step is part of the company’s overall commitment to sustainability, which also includes, promoting the recycling of single-use consumables, encouraging employees to use sustainable forms of transport wherever possible, and using sustainable energy supplies.

Ursula Leuthold, INTEGRA’s dedicated sustainability coordinator, commented: “We constantly review our processes to make them more environmentally friendly. By commissioning these new solar power systems in the USA, we have now reached our next important milestone towards sustainability.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy